Valuation: Gyre Therapeutics, Inc.

Market Cap 483M 433M 398M 361M 674M 45.86B 687M 4.74B 1.9B 24.12B 1.81B 1.77B 76.08B P/E 2026 *
-11.4x
P/E 2027 * -19.4x
Enterprise Value 483M 433M 398M 361M 674M 45.86B 687M 4.74B 1.9B 24.12B 1.81B 1.77B 76.08B EV / Sales 2026 *
4.41x
EV / Sales 2027 * 3.46x
Free-Float
25.6%
Yield 2026 *
-
Yield 2027 * -
1 day-28.94%
1 week-22.14%
1 month-37.86%
3 months-20.78%
6 months-40.69%
Current year-35.48%
1 week 4.52
Extreme 4.515
7.1
1 month 4.52
Extreme 4.515
7.43
Current year 4.52
Extreme 4.515
9.14
1 year 4.52
Extreme 4.515
9.14
3 years 4.52
Extreme 4.515
30.4
5 years 4.52
Extreme 4.515
30.4
10 years 4.52
Extreme 4.515
30.4
Date Insider Type Main position Quantity % Market Cap. Importance
03/08/26 Free

Director

40,000 0.0359%
03/08/26 Free

Director

40,000 0.0359%
10/06/26 Free

Director

40,000 0.0412%
Change 5-day change 1-year change 3-year change Capi.($)
-28.94%-22.14%-41.23%-32.32% 483M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average -2.59%+4.57%+38.70%+172.26% 39.48B
Weighted average by Cap. +0.14%+5.41%+47.88%+176.41%

Financials

2026 *2027 *
Net sales 110M 98.07M 90.21M 81.74M 153M 10.4B 156M 1.08B 432M 5.47B 411M 402M 17.25B 140M 125M 115M 104M 195M 13.26B 198M 1.37B 551M 6.97B 524M 513M 21.99B
Net income -38.85M -34.79M -32.01M -29M -54.21M -3.69B -55.22M -382M -153M -1.94B -146M -143M -6.12B -32.3M -28.93M -26.61M -24.11M -45.07M -3.07B -45.91M -317M -127M -1.61B -121M -119M -5.09B
Net Debt - -
Projected Income Statement - Annual - Gyre Therapeutics, Inc.
Logo Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, and F528. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product and discovery and development of targeted protein degrader and degrader antibody conjugate therapies.
Employees
625
Date Price Change Volume
30/10/26 $4.555 -28.94% 394,081
29/10/26 $6.410 -9.59% 185,320
28/10/26 $7.090 +8.58% 125,172
27/10/26 $6.530 +7.58% 126,373
26/10/26 $6.070 +3.76% 93,374
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Gyre Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.555USD
Average target price
18.67USD
Spread / Average Target
+309.81%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Gyre Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. GYRE Stock